ウイルスベクターとプラスミドDNA製造市場- 世界の産業規模、動向、機会、および予測、2018年～2028年製品タイプ別、用途別、地域別、および競合で区分

世界のウイルスベクターとプラスミドDNA製造市場は、2022年に54億9,000万米ドルと評価され、2028年までのCAGRは10.89%で、予測期間中に目覚ましい成長を遂げると予測されています。

ウイルスベクターおよびプラスミドDNA製造は、バイオテクノロジーおよびバイオ医薬品産業、特に遺伝子治療、ワクチン生産、遺伝子工学などの用途において不可欠なプロセスです。これらのプロセスでは、分子生物学や医学の分野における様々な応用のための重要なツールとして機能するウイルスベクターやプラスミドDNAの生産と精製が行われます。アデノ随伴ウイルス（AAV）、レンチウイルス、レトロウイルスなど、さまざまな種類のウイルスベクターが使用されています。その選択は、特定の用途や標的細胞によって異なります。プラスミドDNA（pDNA）は、バクテリアに見られる円形の二本鎖DNA分子です。組換えタンパク質の生産、遺伝子クローニング、遺伝子治療用ベクターなど、様々な目的のためにバイオテクノロジーで一般的に使用されています。市場の重要な促進要因は、遺伝子治療の研究開発への投資が拡大していることです。ウイルスベクターもプラスミドDNAも、遺伝子治療製品には欠かせない成分です。遺伝性疾患や希少疾患の新規治療法を開発できる可能性があることから、官民双方から多額の資金が集まっています。

CRISPR-Cas9のような遺伝子編集技術を含むバイオテクノロジーの継続的な進歩は、遺伝子治療の可能性を広げています。このため、効率的で安全なデリバリー・システムの必要性が高まっており、ウイルス・ベクターやプラスミドDNAがそれを提供しています。臨床試験でいくつかの遺伝子治療が成功し、FDAやEMAなどの規制当局から承認されたことで、この分野への信頼が高まっています。こうした成功は、ウイルスベクターやプラスミドDNAへのさらなる投資と開発を後押ししています。遺伝子治療は、副作用を最小限に抑え、患者の転帰を改善する、高度に的を絞った治療の可能性を提供します。この標的アプローチは、がん治療やその他の複雑な疾患にとって特に魅力的です。

主要市場促進要因

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のウイルスベクター・プラスミドDNA製造市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品タイプ別（プラスミドDNA、ウイルスベクター、非ウイルスベクター）
  • 用途別（がん、遺伝子疾患、感染症、その他用途）
  • 地域別
  • 企業別（2022年）
• 市場マップ

第6章 アジア太平洋地域のウイルスベクター・プラスミドDNA製造市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品タイプ別
  • 用途別
  • 国別
• アジア太平洋地域国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州ウイルスベクター・プラスミドDNA製造市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品タイプ別
  • 用途別
  • 国別
• 欧州国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米のウイルスベクター・プラスミドDNA製造市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品タイプ別
  • 用途別
  • 国別
• 北米国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米のウイルスベクター・プラスミドDNA製造市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品タイプ別
  • 用途別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのウイルスベクター・プラスミドDNA製造市場の展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 製品タイプ別
  • 用途別
  • 国別
• MEA：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界のウイルスベクターとプラスミドDNA製造市場SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 PESTLE分析

第16章 競合情勢

• Oxford Biomedica PLC
  • Business Overview
  • Company Snapshot
  • Products & Services
  • Financials（In case of listed companies）
  • Recent Developments
  • SWOT Analysis
• Cognate BioServices Inc.
  • Business Overview
  • Company Snapshot
  • Products & Services
  • Financials（In case of listed companies）
  • Recent Developments
  • SWOT Analysis
• Cell and Gene Therapy Catapult Ltd.
  • Business Overview
  • Company Snapshot
  • Products & Services
  • Financials（In case of listed companies）
  • Recent Developments
  • SWOT Analysis
• FinVector Vision Therapies
  • Business Overview
  • Company Snapshot
  • Products & Services
  • Financials（In case of listed companies）
  • Recent Developments
  • SWOT Analysis
• Fujifilm Holdings Corporation（Fujifilm Diosynth Biotechnologies）
  • Business Overview
  • Company Snapshot
  • Products & Services
  • Financials（In case of listed companies）
  • Recent Developments
  • SWOT Analysis
• SIRION Biotech GmbH
  • Business Overview
  • Company Snapshot
  • Products & Services
  • Financials（In case of listed companies）
  • Recent Developments
  • SWOT Analysis
• Merck KGaA Inc.
  • Business Overview
  • Company Snapshot
  • Products & Services
  • Financials（In case of listed companies）
  • Recent Developments
  • SWOT Analysis
• Thermo Fisher Scientific Inc.
  • Business Overview
  • Company Snapshot
  • Products & Services
  • Financials（In case of listed companies）
  • Recent Developments
  • SWOT Analysis
• Uniqure NV
  • Business Overview
  • Company Snapshot
  • Products & Services
  • Financials（In case of listed companies）
  • Recent Developments
  • SWOT Analysis
• Catalent Inc.
  • Business Overview
  • Company Snapshot
  • Products & Services
  • Financials（In case of listed companies）
  • Recent Developments
  • SWOT Analysis

第17章 戦略的提言

Global Viral Vector and Plasmid DNA Manufacturing Market has valued at USD 5.49 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 10.89% through 2028. Viral vector and plasmid DNA manufacturing are essential processes in biotechnology and biopharmaceutical industries, particularly for applications like gene therapy, vaccine production, and genetic engineering. These processes involve the production and purification of viral vectors and plasmid DNA, which serve as crucial tools for various applications in the field of molecular biology and medicine. Different types of viral vectors are used, such as adeno-associated viruses (AAVs), lentiviruses, retroviruses, and others. The choice depends on the specific application and target cells. Plasmid DNA (pDNA) is a circular, double-stranded DNA molecule found in bacteria. It is commonly used in biotechnology for various purposes, including the production of recombinant proteins, gene cloning, and as a vector for gene therapy. A significant driver for the market is the growing investment in gene therapy research and development. Both viral vectors and plasmid DNA are essential components in gene therapy products. The potential to develop novel treatments for genetic and rare diseases has attracted substantial funding from both public and private sectors.

Ongoing advancements in biotechnology, including gene editing techniques like CRISPR-Cas9, have expanded the possibilities for gene therapy. This has driven the need for efficient and safe delivery systems, which viral vectors and plasmid DNA provide. The success of several gene therapies in clinical trials and their subsequent approvals by regulatory agencies, such as the FDA and EMA, have boosted confidence in the field. These successes encourage further investment and development in viral vectors and plasmid DNA. Gene therapies offer the potential for highly targeted treatments, which can minimize side effects and improve patient outcomes. This targeted approach is particularly attractive for cancer treatments and other complex diseases.

Key Market Drivers

Advancements in Biotechnology

Technologies like CRISPR-Cas9 have revolutionized genetic engineering. They allow precise and efficient modification of genes in various organisms, holding tremendous potential for treating genetic diseases, creating genetically modified organisms (GMOs), and advancing basic research. Advances in genomics have made it possible to sequence entire genomes quickly and cost-effectively. This has paved the way for personalized medicine, where treatments are tailored to an individual's genetic makeup, increasing treatment efficacy, and reducing side effects. The biopharmaceutical industry has grown significantly, producing complex drugs like monoclonal antibodies, vaccines, and gene therapies. Biomanufacturing techniques have improved, leading to more efficient and cost-effective production of these drugs. Synthetic biology involves designing and constructing biological parts, devices, and systems to perform specific functions. This field has led to the creation of synthetic organisms, biosensors, and biofuels. Stem cell research has advanced significantly, leading to the development of stem cell therapies for various diseases and injuries. These therapies have the potential to regenerate damaged tissues and organs. Advances in bioinformatics have enabled the efficient storage, analysis, and interpretation of vast amounts of biological data. This is crucial for genomics, drug discovery, and understanding complex biological processes. Biotechnology is being used to address environmental challenges, such as pollution remediation, waste management, and the development of biofuels and bioplastics.

Genetically modified crops (GMOs) have been developed to improve crop yield, resistance to pests and diseases, and nutritional content. This technology has the potential to enhance food security and sustainability. Biotechnology has led to the development of novel vaccines and immunotherapies for infectious diseases and cancer. These treatments harness the body's immune system to combat diseases. The study of the human microbiome has revealed the crucial role of microorganisms in human health. Advances in microbiome research have implications for understanding and treating various diseases. The integration of nanotechnology with biotechnology has led to the development of nanoparticles and nanoscale tools for drug delivery, imaging, and diagnostics. 3D bioprinting technology allows the fabrication of complex tissues and organs using living cells. This has potential applications in regenerative medicine and tissue engineering. Biotechnology is used to develop biosensors and bioremediation techniques for monitoring and cleaning up environmental pollutants. AI and machine learning are increasingly used to analyze biological data, model biological systems, and assist in drug discovery and development. This factor will help in the development of Global Viral Vector and Plasmid DNA Manufacturing Market.

Increasing Investment in Gene Therapy

Gene therapy involves the introduction of therapeutic genes or genetic material into a patient's cells to treat or prevent disease. Viral vectors and plasmid DNA serve as essential tools for delivering these therapeutic genes into target cells. Viral vectors, such as adeno-associated viruses (AAVs) or lentiviruses, are used for in vivo gene therapy, while plasmid DNA is often employed in ex vivo gene therapy. The development of gene therapies starts with extensive research and preclinical studies. This research phase often involves testing different viral vectors and plasmid DNA constructs to optimize delivery and expression of therapeutic genes. Investment in research drives the demand for these materials. Gene therapies must go through rigorous clinical trials to demonstrate safety and efficacy before they can be approved for widespread use. These trials require substantial quantities of viral vectors and plasmid DNA, especially as they progress to larger patient populations. Once a gene therapy is proven effective in clinical trials, it enters the commercialization phase. This involves scaling up production to meet market demand. Viral vectors and plasmid DNA manufacturers play a critical role in providing the necessary materials for large-scale production.

Gene therapy has a wide range of applications beyond rare genetic diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. The versatility of viral vectors and plasmid DNA makes them suitable for various therapeutic areas, further increasing demand. Regulatory agencies like the FDA in the United States have introduced expedited pathways and designations for promising gene therapies. These pathways encourage investment in gene therapy development and manufacturing. Success stories in gene therapy, such as the approval of Luxturna and Zolgensma, have bolstered investor confidence in the field. Increased funding from both venture capital and pharmaceutical companies fuels the development and manufacturing of viral vectors and plasmid DNA. The demand for gene therapies is not limited to a single region. It is a global market, and as more countries recognize the potential of gene therapy, there is a growing need for a reliable supply of viral vectors and plasmid DNA worldwide. Ongoing advancements in bioprocessing and manufacturing techniques for viral vectors and plasmid DNA are making production more efficient and cost-effective, aligning with the needs of a growing market. Gene therapy offers the potential for transformative treatments, which attracts investment and support from patients, advocacy groups, and healthcare systems. This factor will pace up the demand of Global Viral Vector and Plasmid DNA Manufacturing Market.

Technological Advancements

Single-use bioreactors have gained popularity in biopharmaceutical manufacturing, including viral vector and plasmid DNA production. These disposable systems offer flexibility, reduce the risk of contamination, and decrease setup times compared to traditional stainless-steel bioreactors. Advances in cell culture media and bioprocess optimization have led to higher cell densities and productivity. This results in increased yields of viral vectors and plasmid DNA from bioreactors, reducing production costs. The development of stable and high-yielding cell lines for viral vector and plasmid DNA production has led to more efficient and consistent manufacturing processes. Modified cell lines optimized for specific applications can increase productivity. New chromatography and purification techniques have been developed to enhance the purity and yield of viral vectors and plasmid DNA. Improved resin materials, column designs, and purification strategies contribute to higher product quality. Closed and automated systems minimize the risk of contamination, reduce operator intervention, and increase the reproducibility of manufacturing processes. These systems are particularly important in the production of viral vectors and plasmid DNA for clinical applications. Advances in analytical techniques and quality control methods enable real-time monitoring and characterization of viral vector and plasmid DNA products. This ensures product consistency and helps meet regulatory requirements.

Process Analytical Technology (PAT) tools, including sensors and data analytics, are integrated into manufacturing processes to provide real-time data and enable process control and optimization. This enhances product quality and reduces the need for time-consuming offline testing. Scalable manufacturing platforms are crucial to meet the increasing demand for viral vectors and plasmid DNA. Modular and flexible systems allow for easy scale-up from research and development to commercial production. New platforms and technologies for viral vector production, such as baculovirus-insect cell systems and transient transfection using suspension-adapted cell lines, offer alternatives to traditional adherent cell culture methods. Continuous manufacturing approaches are being explored to replace batch processes in viral vector and plasmid DNA production. Continuous systems offer greater productivity, reduced production time, and smaller facility footprints. Enhanced safety measures, such as containment systems and viral inactivation technologies, have been developed to mitigate the risks associated with handling viral vectors, especially when working with pathogenic viruses. Overall cost reduction strategies, including more efficient use of resources, optimization of raw materials, and improved process yields, contribute to the affordability and accessibility of viral vectors and plasmid DNA products. Manufacturers are increasingly focused on sustainability, exploring eco-friendly materials and processes to reduce the environmental impact of viral vector and plasmid DNA production. This factor will accelerate the demand of Global Viral Vector and Plasmid DNA Manufacturing Market.

Key Market Challenges

Costs and Pricing Pressures

Viral vector and plasmid DNA manufacturing processes can be complex, involving multiple steps and the use of specialized equipment and materials. These processes can be costly to establish and operate, leading to higher production costs. As gene therapies progress from research and development to commercial production, companies face the challenge of scaling up manufacturing processes. Achieving economies of scale while maintaining product quality is a delicate balance that impacts costs. Meeting stringent regulatory requirements for gene therapy products adds additional costs to manufacturing. Companies must invest in quality control, documentation, and compliance measures, which can be resource intensive. Ensuring the safety and efficacy of viral vectors and plasmid DNA products requires rigorous quality control and assurance processes. These processes can increase production costs, especially when addressing deviations or maintaining consistent quality. Building and maintaining state-of-the-art manufacturing facilities and cleanrooms compliant with Good Manufacturing Practices (GMP) standards is a significant upfront investment that can lead to cost pressures. The cost of raw materials, such as cell culture media, growth factors, and purification reagents, can impact overall manufacturing costs. Supply chain disruptions or fluctuations in raw material prices can increase these costs. Proper disposal of waste materials generated during manufacturing, including biological waste and hazardous materials, can be expensive and regulated.

Ethical and Societal Considerations

The ability to modify genes raises concerns about the potential for genetic enhancement and the creation of designer babies. Ethical debates revolve around the boundaries of gene editing and the implications for future generations. Ensuring that patients fully understand the risks and benefits of gene therapy is crucial. Obtaining informed consent from patients and, in some cases, their families or guardians, can be challenging, especially when dealing with vulnerable populations. There are concerns about equitable access to gene therapies. High costs can limit access to these treatments, potentially exacerbating health disparities. Ensuring affordability and accessibility for all patients is an ethical imperative. Gene therapies are relatively new, and their long-term safety and efficacy are not always well-understood. Ethical considerations include the need for ongoing monitoring and the obligation to report adverse events. Editing the germline (sperm and egg cells) raises significant ethical questions. Permanent genetic changes made to the germline can be passed on to future generations, potentially altering the human gene pool. Obtaining informed consent for germline editing is particularly complex, as the implications extend to descendants who cannot provide consent. Global discussions are ongoing to establish guidelines and regulations for such interventions. Gene editing techniques can sometimes have unintended "off-target" effects, potentially causing harm. Ethical considerations include the need to minimize off-target effects and disclose any risks to patients.

Key Market Trends

Cell and Gene Therapy Ecosystem Development

Collaboration among academic institutions, research organizations, and biopharmaceutical companies is crucial for advancing cell and gene therapy technologies. These partnerships enable the exchange of knowledge, expertise, and resources, accelerating the development of innovative therapies. Many countries have established specialized research centers and institutes dedicated to cell and gene therapy research. These centers serve as hubs for cutting-edge research and provide a nurturing environment for scientists and innovators. Biotechnology clusters or hubs, often located in regions with a strong biotech presence, foster innovation, collaboration, and investment in cell and gene therapy. Examples include the Boston-Cambridge area in the United States and the Golden Triangle in the United Kingdom. Governments and private entities are providing funding and grants to support cell and gene therapy research and development. These initiatives help attract top talent and stimulate innovation in the field. Regulatory agencies are actively engaged in shaping policies and pathways for cell and gene therapies. They provide guidance, expedited review processes, and incentives to facilitate product development and approvals. Investments in manufacturing facilities and infrastructure that meet Good Manufacturing Practices (GMP) standards are essential. This includes the construction of specialized cell and gene therapy manufacturing plants. Patient advocacy organizations and support groups play a vital role in advancing cell and gene therapies. They raise awareness, advocate for patients' needs, and provide valuable insights to researchers and developers. Venture capital firms and investors are increasingly interested in funding cell and gene therapy startups. This investment activity drives innovation and entrepreneurship in the ecosystem.

Segmental Insights

Product Type Insights

In 2022, the Global Viral Vector and Plasmid DNA Manufacturing Market largest share was held by Plasmid DNA segment and is predicted to continue expanding over the coming years. Plasmid DNA is used in various applications beyond gene therapy, including vaccine development, protein expression, and research purposes. This versatility allows it to have a broader market reach and more diverse customer base compared to viral vectors, which are primarily used in gene therapy. Plasmid DNA plays a crucial role in the development of DNA-based vaccines, which have gained attention due to their potential in preventing infectious diseases. The COVID-19 pandemic led to increased demand for DNA vaccines, boosting the plasmid DNA manufacturing market. Many biopharmaceutical and biotech companies already have established infrastructure and expertise for plasmid DNA production, making it a convenient choice for in-house research and development.

Application Insights

In 2022, the Global Viral Vector and Plasmid DNA Manufacturing Market cancer segment to witness robust growth in the forecast period and is predicted to continue expanding over the coming years. Cancer remains a leading cause of mortality worldwide, and there is a substantial unmet medical need for more effective treatments. Gene therapy, including the use of viral vectors and plasmid DNA, holds promise as a novel approach to targeting and treating various types of cancer. Ongoing research in oncology has led to a deeper understanding of the genetic and molecular basis of cancer. This knowledge has paved the way for the development of gene therapies that can target specific genetic mutations and pathways responsible for cancer growth. Gene therapies can be designed to target cancer cells specifically, minimizing damage to healthy tissues and reducing side effects compared to traditional chemotherapy and radiation therapy. This targeted approach is particularly attractive for treating cancer.

Regional Insights

The North America region dominates the Global Viral Vector and Plasmid DNA Manufacturing Market in 2022. North America, particularly the United States, has a well-developed and mature biopharmaceutical industry. The region is home to numerous biotechnology and pharmaceutical companies with extensive experience in research, development, and manufacturing of biologics, including viral vectors and plasmid DNA. North America has been at the forefront of gene therapy research and development. The United States has seen significant investment and progress in the field, leading to a higher number of clinical trials and commercialization efforts involving viral vectors and plasmid DNA. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) have provided clear pathways and guidance for the development and approval of gene therapies. This regulatory clarity has attracted investments and encouraged companies to pursue clinical development and manufacturing activities in the region.

Key Market Players

Oxford Biomedica PLC

Cognate BioServices Inc.

Cell and Gene Therapy Catapult Ltd.

FinVector Vision Therapies

Fujifilm Holdings Corporation (Fujifilm Diosynth Biotechnologies)

SIRION Biotech GmbH

Merck KGaA Inc.

Thermo Fisher Scientific

Uniqure NV

Catalent Inc.

Report Scope:

In this report, the Global Viral Vector and Plasmid DNA Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Viral Vector and Plasmid DNA Manufacturing Market, By Product Type:

• Plasmid DNA
• Viral Vector
• Non-viral Vector

Viral Vector and Plasmid DNA Manufacturing Market, By Application:

• Cancer
• Genetic Disorder
• Infectious Disease
• Other Applications

Global Viral Vector and Plasmid DNA Manufacturing Market, By region:

• North America
• United States
• Canada
• Mexico
• Asia-Pacific
• China
• India
• South Korea
• Australia
• Japan
• Europe
• Germany
• France
• United Kingdom
• Spain
• Italy
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Viral Vector and Plasmid DNA Manufacturing Market.

Available Customizations:

• Global Viral Vector and Plasmid DNA Manufacturing Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Viral Vector and Plasmid DNA Manufacturing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Plasmid DNA, Viral Vector, and Non-viral Vector)
  • 5.2.2. By Application (Cancer, Genetic Disorder, Infectious Disease, and Other Applications)
  • 5.2.3. By Region
  • 5.2.4. By Company (2022)
• 5.3. Market Map

6. Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Application
  • 6.3.2. India Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Australia Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Application
  • 6.3.4. Japan Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Product Type
      • 6.3.4.2.2. By Application
  • 6.3.5. South Korea Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Product Type
      • 6.3.5.2.2. By Application

7. Europe Viral Vector and Plasmid DNA Manufacturing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Application
  • 7.3.2. Germany Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Application
  • 7.3.3. Spain Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Application
  • 7.3.5. United Kingdom Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Application

8. North America Viral Vector and Plasmid DNA Manufacturing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Application
  • 8.3.2. Mexico Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Canada Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Application

9. South America Viral Vector and Plasmid DNA Manufacturing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Application
  • 9.3.2. Argentina Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Application
  • 9.3.3. Colombia Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Application

10. Middle East and Africa Viral Vector and Plasmid DNA Manufacturing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Saudi Arabia Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Application
  • 10.3.3. UAE Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Viral Vector and Plasmid DNA Manufacturing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Oxford Biomedica PLC
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Cognate BioServices Inc.
  • 16.2.1. Business Overview
  • 16.2.2. Company Snapshot
  • 16.2.3. Products & Services
  • 16.2.4. Financials (In case of listed companies)
  • 16.2.5. Recent Developments
  • 16.2.6. SWOT Analysis
• 16.3. Cell and Gene Therapy Catapult Ltd.
  • 16.3.1. Business Overview
  • 16.3.2. Company Snapshot
  • 16.3.3. Products & Services
  • 16.3.4. Financials (In case of listed companies)
  • 16.3.5. Recent Developments
  • 16.3.6. SWOT Analysis
• 16.4. FinVector Vision Therapies
  • 16.4.1. Business Overview
  • 16.4.2. Company Snapshot
  • 16.4.3. Products & Services
  • 16.4.4. Financials (In case of listed companies)
  • 16.4.5. Recent Developments
  • 16.4.6. SWOT Analysis
• 16.5. Fujifilm Holdings Corporation (Fujifilm Diosynth Biotechnologies)
  • 16.5.1. Business Overview
  • 16.5.2. Company Snapshot
  • 16.5.3. Products & Services
  • 16.5.4. Financials (In case of listed companies)
  • 16.5.5. Recent Developments
  • 16.5.6. SWOT Analysis
• 16.6. SIRION Biotech GmbH
  • 16.6.1. Business Overview
  • 16.6.2. Company Snapshot
  • 16.6.3. Products & Services
  • 16.6.4. Financials (In case of listed companies)
  • 16.6.5. Recent Developments
  • 16.6.6. SWOT Analysis
• 16.7. Merck KGaA Inc.
  • 16.7.1. Business Overview
  • 16.7.2. Company Snapshot
  • 16.7.3. Products & Services
  • 16.7.4. Financials (In case of listed companies)
  • 16.7.5. Recent Developments
  • 16.7.6. SWOT Analysis
• 16.8. Thermo Fisher Scientific Inc.
  • 16.8.1. Business Overview
  • 16.8.2. Company Snapshot
  • 16.8.3. Products & Services
  • 16.8.4. Financials (In case of listed companies)
  • 16.8.5. Recent Developments
  • 16.8.6. SWOT Analysis
• 16.9. Uniqure NV
  • 16.9.1. Business Overview
  • 16.9.2. Company Snapshot
  • 16.9.3. Products & Services
  • 16.9.4. Financials (In case of listed companies)
  • 16.9.5. Recent Developments
  • 16.9.6. SWOT Analysis
• 16.10. Catalent Inc.
  • 16.10.1. Business Overview
  • 16.10.2. Company Snapshot
  • 16.10.3. Products & Services
  • 16.10.4. Financials (In case of listed companies)
  • 16.10.5. Recent Developments
  • 16.10.6. SWOT Analysis

17. Strategic Recommendations

About Us & Disclaimer